WebApr 11, 2024 · The primary target variable is safety, defined as the maximal organ toxicity to each organ system according to CTC criteria as well as the number of AEs of grade III or greater within the first 30 days (± 3) after transplantation [ Time Frame: inclusion until day 30 (± 3) after transplantation ] WebCytogenetically normal acute myeloid leukemia Description Cytogenetically normal acute myeloid leukemia (CN-AML) is one form of a cancer of the blood-forming tissue …
Biological and clinical influences of NPM1 in acute myeloid leukemia …
WebAcute myeloid leukemia (AML) is a heterogeneous disease characterized by malignant proliferation of myeloid hematopoietic stem/progenitor cells. NPM1 represents the most frequently mutated gene in AML and approximately 30% of AML cases carry NPM1 mutations. Mutated NPM1 result in the cytoplasmic localization of NPM1 (NPM1c). on the peak fleece
Small RNA sequencing profiles of mir-181 and mir-221, the most …
WebCarnitine palmitoyl transferase 1A (CPT1A) protein catalyzes the rate-limiting step of Fatty-acid oxidation (FAO) pathway, which can promote cell proliferation and suppress … WebAcute myeloid leukemia (AML) Acute lymphoblastic leukemia (ALL) Chronic myeloid leukemia (CML) Myeloproliferative diseases (MPD) Myelodysplastic syndrome (MDS) Hematologic Oncology Bone marrow failure states (aplastic anemia, hypoplastic MDS) Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Myelofibrosis Research Interests: WebNov 6, 2008 · Acute myeloid leukaemia is a highly malignant haematopoietic tumour that affects about 13,000 adults in the United States each year. The treatment of this disease has changed little in the past... on the peak or at the peak